BET Proteins as _targets for Anticancer Treatment
- PMID: 29263030
- DOI: 10.1158/2159-8290.CD-17-0605
BET Proteins as _targets for Anticancer Treatment
Abstract
Bromodomain and extraterminal domain (BET) proteins are epigenetic readers that regulate gene expression and are involved in cancer pathogenesis. Over the last years, several BET inhibitors have been developed and clinically tested. Results from the first clinical trials show limited single-agent activity in a small subset of patients with hematologic malignancies and in NUT carcinoma. Adverse events have been observed and may limit treatment compliance. Here, we review the preclinical rationale for _targeting BET proteins in cancer and the preliminary results from clinical trials, and outline future directions for the use of BET inhibitors as antitumor agents.Significance: BET inhibitors represent a new class of anticancer agents. Results from the first clinical trials confirm the antitumor potential of BET inhibitors, but their efficacy as single agents seems to be limited. Based on preclinical data, combination therapies with other anticancer agents and the development of a new generation of compounds may open new possibilities for _targeting BET proteins as effective anticancer strategies. Cancer Discov; 8(1); 24-36. ©2017 AACR.
©2017 American Association for Cancer Research.
Similar articles
-
The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8326-31. doi: 10.1073/pnas.1424220112. Epub 2015 Jun 25. Proc Natl Acad Sci U S A. 2015. PMID: 26111795 Free PMC article.
-
Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML).Expert Opin Investig Drugs. 2017 Jul;26(7):803-811. doi: 10.1080/13543784.2017.1335711. Epub 2017 Jun 9. Expert Opin Investig Drugs. 2017. PMID: 28541716 Review.
-
BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.Theranostics. 2016 Jan 1;6(2):219-30. doi: 10.7150/thno.13178. eCollection 2016. Theranostics. 2016. PMID: 26877780 Free PMC article.
-
_targeting BET bromodomains for cancer treatment.Epigenomics. 2015;7(3):487-501. doi: 10.2217/epi.14.91. Epigenomics. 2015. PMID: 26077433 Review.
-
Bromodomain and extraterminal domain protein bromodomain inhibitor based cancer therapeutics.Curr Opin Oncol. 2021 Sep 1;33(5):526-531. doi: 10.1097/CCO.0000000000000763. Curr Opin Oncol. 2021. PMID: 34280171 Review.
Cited by
-
PROTAC: An Effective _targeted Protein Degradation Strategy for Cancer Therapy.Front Pharmacol. 2021 May 7;12:692574. doi: 10.3389/fphar.2021.692574. eCollection 2021. Front Pharmacol. 2021. PMID: 34025443 Free PMC article. Review.
-
The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by _targeting Superenhancer-Related Genes in Neuroblastoma.J Immunol Res. 2022 Nov 16;2022:7945884. doi: 10.1155/2022/7945884. eCollection 2022. J Immunol Res. 2022. PMID: 36438198 Free PMC article.
-
The Bidirectional Relationship Between Cancer Epigenetics and Metabolism.Annu Rev Cancer Biol. 2021 Mar;5(1):235-257. doi: 10.1146/annurev-cancerbio-070820-035832. Epub 2020 Nov 30. Annu Rev Cancer Biol. 2021. PMID: 34109280 Free PMC article.
-
Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1.J Clin Invest. 2020 Apr 1;130(4):1782-1792. doi: 10.1172/JCI126327. J Clin Invest. 2020. PMID: 31874106 Free PMC article.
-
Inducing the Degradation of Disease-Related Proteins Using Heterobifunctional Molecules.Molecules. 2019 Sep 8;24(18):3272. doi: 10.3390/molecules24183272. Molecules. 2019. PMID: 31500395 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
